Global Bruton Tyrosine Kinase (BTK) Inhibitors Market

Report ID : 1242 | Published : 2022-06-07 | Pages: | Format: PDF/EXCEL

The Global Bruton Tyrosine Kinase (BTK) Inhibitors Market is estimated to reach over USD 22.46 billion by 2030, exhibiting a CAGR of 10% during the forecast period. 

Non-receptor tyrosine kinase inhibitors that target B-cell receptors are called Bruton's tyrosine kinase (BTK) inhibitors to modulate B-cell signalling, proliferation, growth, and differentiation. B-cell leukaemia, lymphomas, haematological malignancies, and graft versus host disease are treated with Bruton's tyrosine kinase (BTK) inhibitors (GVDH). Imbruvica (ibrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that is approved for the treatment of Non-lymphoma, Hodgkin's haematological malignancies, and GVDH. There are currently around 20 Bruton's tyrosine kinase (BTK) inhibitors in development. The global Bruton's tyrosine kinase (BTK) Inhibitors market is expected to increase further in the future due to the current augmentations of the growing healthcare industry and therapeutic demands. There are likely to be changed in the business, such as shifting supply chains, saving money, automating tasks, and putting more focus on the customer. Companies that recognize industry trends and align their operations will earn significant market share. Emerging market trends, main driving forces, company challenges, and Bruton's Tyrosine Kinase (BTK) Inhibitors markets are all covered in this study.

However, Legal hurdles, rising cardiovascular illnesses, drug approval roadblocks, and off-targeting of first-generation Bruton's tyrosine kinase (BTK) inhibitors, on the other hand, will slow the market's growth rate. The market for Bruton tyrosine kinase (BTK) inhibitors will be challenged by a shortage of skilled experts and a lack of healthcare infrastructure in developing economies. Furthermore, side effects associated with Bruton tyrosine kinase (BTK) inhibitors, as well as the rising frequency of cardiovascular illnesses, would act as market barriers, slowing the market's growth pace from 2021 to 2028. Companies and academics, on the other hand, are collaborating to identify obstacles and possibilities that potentially impact Brutons Tyrosine Kinase (BTK) Inhibitors research and development. Novel ways to treat/improve Brutons Tyrosine Kinase (BTK) Inhibitors are the focus of the medicines in development.

Market Segmentation:

The Bruton Tyrosine Kinase (BTK) Inhibitors Market is segmented on the basis of product type and application. Based on product type, the market is segmented as         IC50<1nM, 1nM< IC50<5nM, and IC50>5nM. By application, the market is segmented into Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Other Selective B Cell Malignancies, Chronic Graft-versus-host Disease, and Others.

 

Chronic Lymphocytic Leukemia (CLL) segment witnessed growth at a rapid rate.

Along with its demonstrated success in treatment, Chronic Lymphocytic Leukemia (CLL) dominates the BTK Inhibitors market, followed by lymphoma. The FDA authorised Brukinsa in 2019 for the treatment of mantle cell lymphoma.

In the region, the North America Bruton Tyrosine Kinase (BTK) Inhibitors Market holds a significant revenue share.

With a market share of roughly 40% of the global Bruton Tyrosine Kinase (BTK) Inhibitors market revenue in 2021, North America emerged as the leading market. The market for Bruton Tyrosine Kinase (BTK) Inhibitors in North America has been growing as the number of research projects in the region has increased. Along with the presence of key industry players in the region, the market in the region is predicted to develop. Furthermore, the region's growing frequency of chronic diseases presents lucrative growth potential for Bruton Tyrosine Kinase (BTK) Inhibitors.

However, the Asia-Pacific area has seen a spike in biotechnology research and therapeutic development. The market for Bruton's tyrosine kinase (BTK) inhibitors in APAC is increasing at the quickest rate, with significant contributions from South Asian nations like China and India and East Asian countries like Japan.

Competitive Landscape

The leading players are now focusing on strategies such as product innovations, mergers & acquisitions, new developments, joint ventures, collaborations, and partnerships to improve their market position in the global Bruton Tyrosine Kinase (BTK) Inhibitors market. Some of the key market players are, Pfizer Inc, Acerta Pharma, Aptose Biosciences, ArQule, BeiGene, Carna Biosciences, Celgene Corporation, Eternity Bioscience, Hanmi Pharmaceutical, KBP Biosciences, Loxo Oncology, LSK BioPharma, Merck, Ono Pharmaceutical, Pharmacyclics, Principia Biopharma, Tolero, X-Rx, Zhejiang DTRM Biopharma, Johnson & Johnson, AstraZeneca, Roche, Sunesis, Takeda, Bristol- Myers Squibb, Gilead Sciences, AbbVie, Biogen, INNOCARE, ACEA Biosciences, and Other Prominent Players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Snapshot

Chapter 4. Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Competitive Landscape & Market Share Analysis

4.7. COVID 19 Impact Analysis

Chapter 5. Market Segmentation 1: Product Type Estimates & Trend Analysis

5.1. Product Type & Market Share, 2020 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Product Type:

5.2.1. IC50<1nM

5.2.2. 1nM< IC50<5nM

5.2.3. IC50>5nM

Chapter 6. Market Segmentation 2: Application Estimates & Trend Analysis

6.1. Application Type & Market Share, 2020& 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2028 for the following Application Type:

6.2.1. Chronic Lymphocytic Leukemia (cll)

6.2.2. Follicular Lymphoma

6.2.3. Mantle Cell Lymphoma

6.2.4. Marginal Zone Lymphoma

6.2.5. Small Lymphocytic Lymphoma

6.2.6. Waldenstrom Macroglobulinemia

6.2.7. Other Selective B Cell Malignancies

6.2.8. Chronic Graft-versus-host Disease

6.2.9. Other

Chapter 7. Bruton Tyrosine Kinase (BTK) Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) estimates and forecasts by Product, 2020-2028

7.1.2. North America Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) estimates and forecasts by Application, 2020-2028

7.1.3. North America Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2020-2028

7.2. Europe

7.2.1. Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Product, 2020-2028

7.2.2. Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Application, 2020-2028

7.2.3. Europe Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by country, 2020-2028

7.3. Asia Pacific

7.3.1. Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Product, 2020-2028

7.3.2. Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Application, 2020-2028

7.3.3. Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by country, 2020-2028

7.4. Latin America

7.4.1. Latin America Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Product, (US$ Million)

7.4.2. Latin America Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Application, (US$ Million)

7.4.3. Latin America Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2020-2028

7.5. Middle East & Africa

7.5.1. Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Product, (US$ Million)

7.5.2. Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by Application, (US$ Million)

7.5.3. Middle East & Africa Bruton Tyrosine Kinase (BTK) Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2020-2022

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. Pfizer Inc

8.2.2. Acerta Pharma

8.2.3. Aptose Biosciences

8.2.4. ArQule

8.2.5. BeiGene

8.2.6. Carna Biosciences

8.2.7. Celgene Corporation

8.2.8. Eternity Bioscience

8.2.9. Hanmi Pharmaceutical

8.2.10. KBP Biosciences

8.2.11. Loxo Oncology

8.2.12. LSK BioPharma

8.2.13. Merck

8.2.14. Ono Pharmaceutical

8.2.15. Pharmacyclics

8.2.16. Principia Biopharma

8.2.17. Tolero

8.2.18. X-Rx

8.2.19. Zhejiang DTRM Biopharma

8.2.20. Johnson & Johnson

8.2.21. AstraZeneca

8.2.22. Roche

8.2.23. Sunesis

8.2.24. Takeda

8.2.25. Bristol- Myers Squibb

8.2.26. Gilead Sciences

8.2.27. AbbVie

8.2.28. Biogen

8.2.29. INNOCARE

8.2.30. ACEA Biosciences

8.2.31. Other Prominent Players

Segmentation of Bruton Tyrosine Kinase (BTK) Inhibitors Market-

By Product Type-

  • IC50<1nM
  • 1nM< IC50<5nM
  • IC50>5nM

By Application-

  • Chronic Lymphocytic Leukemia (cll)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Small Lymphocytic Lymphoma
  • Waldenstrom Macroglobulinemia
  • Other Selective B Cell Malignancies
  • Chronic Graft-versus-host Disease
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa

Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients